Septerna (SEPN) Change in Account Payables (2023 - 2026)
Septerna's quarterly Change in Account Payables came in at -$2.3 million in Q1 2026, down 294.1% year-on-year from $1.2 million in Q1 2025, and down 137.91% quarter-over-quarter from $6.1 million in Q4 2025.
Septerna has reported Change in Account Payables for 4 years, with the latest figure at -$2.3 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 294.1% year-over-year to -$2.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 million (up 51.8% YoY), and the FY2025 full-year result was $6.6 million, up 813.28% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$2.3 million, down from $6.1 million in the prior quarter.
- The five-year high for Change in Account Payables was $6.1 million in Q4 2025, with the low at -$2.9 million in Q3 2025.
- Average Change in Account Payables over 4 years is $550200.0, with a median of $167500.0 recorded in 2023.
- Year-over-year, Change in Account Payables slumped 454.81% in 2024 and jumped 1214.21% in 2025.
- Tracing SEPN's Change in Account Payables over 4 years: stood at $478000.0 in 2023, then tumbled by 454.81% to -$1.7 million in 2024, then surged by 458.08% to $6.1 million in 2025, then sank by 137.91% to -$2.3 million in 2026.
- The last three Change in Account Payables figures came in at -$2.3 million (Q1 2026), $6.1 million (Q4 2025), and -$2.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | -2.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.30 Mn |
| Mar 31, 2026 | -2.30 Mn |
| Dec 31, 2025 | 6.07 Mn |
| Dec 31, 2025 | 6.07 Mn |
| Sep 30, 2025 | -2.85 Mn |
| Sep 30, 2025 | -2.85 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | 1.19 Mn |
| Mar 31, 2025 | 1.19 Mn |
| Dec 31, 2024 | -1.70 Mn |
| Dec 31, 2024 | -1.70 Mn |
| Sep 30, 2024 | 2.76 Mn |
| Sep 30, 2024 | 2.76 Mn |
| Jun 30, 2024 | -197,000.00 |
| Jun 30, 2024 | -197,000.00 |
| Mar 31, 2024 | -143,000.00 |
| Mar 31, 2024 | -143,000.00 |
| Dec 31, 2023 | 478,000.00 |
| Dec 31, 2023 | 478,000.00 |